ASC42 + entecavir + peginterferon alfa-2a

This is a combination therapy consisting of three agents: - **ASC42**: A potent, selective, orally administered farnesoid X receptor (FXR) agonist developed by Ascletis Pharma. ASC42 uniquely inhibits the transcription of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) into HBV RNA, potentially reducing both HBV RNA and cccDNA stability. Its primary indication is chronic hepatitis B, where it may contribute to functional cure through antiviral activity at the level of HBV cccDNA transcription[1][3]. - **Entecavir**: A hepatitis B virus polymerase inhibitor nucleoside analogue, used for the treatment of chronic hepatitis B. It is an approved first-line therapy for HBV. - **Peginterferon alfa-2a**: A recombinant, pegylated interferon that acts as an immunomodulator and antiviral by binding to type I interferon receptors, activating the JAK/STAT pathway, and upregulating genes involved in antiviral responses. It is approved for the treatment of chronic hepatitis B and C[2][4][6]. This combination is being studied in Phase II clinical trials for the treatment of chronic hepatitis B, aiming for a functional cure by targeting viral replication, stability, and immune response[1][3].

Other names

entecavirpegylated interferon alpha-2aPEG-IFN-α-2a